Samsung Biologics raises annual estimated earnings to W3.6t
Samsung Biologics has raised the full-year earnings estimate in its company guidance again to 3.6 trillion won ($2.6 billion) for this year, up some 20 percent from last year, according to its regulatory filing released on Wednesday.
It was the second time this year for Samsung Biologics to increase the estimate of its annual earnings. Earlier in April, the company raised its estimated earnings from sales to 3.52 trillion won.
“(Samsung Biologics) has readjusted (the estimated earnings in its) annual company guidance again, mainly based on large-sized contract manufacturing orders from international pharmaceutical companies this year,” an official from Samsung Biologics said.
In 2023, the company’s accumulated order value reached some 2.7 trillion won, backed by its large-scale contracts with Pfizer, Novartis and BMS.
Many of its clients, including GSK, Roche, Novartis, Pfizer and Eli Lilly, have also agreed with Samsung Biologics to expand their existing contract manufacturing deals, helping the company to post improved earnings this year.
The combined value of deals that have been expanded from existing deals has reached 986.2 billion won as of September, according to Samsung Biologics.
Samsung Biologics expects its earnings to improve particularly in the third quarter, in which revenue from the company’s fourth plant will start to be included.
“The utilization rate of the fourth plant has been increasing faster than expected,” the official from Samsung Biologics said.
(责任编辑:부모와 아이)
下一篇:Hyundai Rotem to showcase new ground weapons systems at Seoul expo
- ·[New in Korean] Ancient Korean mummy unearthed in Irish peatland
- ·Apple to launch iPhone15 series in S. Korea on Oct. 13
- ·Opposition head pleads for support in ‘fight against Yoon dictatorship’
- ·Surveillance cameras to be a must in hospital operating rooms
- ·[New in Korean] Year 2020 revisited under shadow of disconnection
- ·PM arrives in China for Asian Games, meeting with Xi
- ·SC Bank Korea CEO nominated for fourth term
- ·Chief justice seat at top court left vacant amid Assembly chaos
- ·[Herald Review] ‘Carmen’ redefines iconic femme fatale as stalking victim
- ·Hospital visits during Chuseok cost up to 50% more
- ·Hyundai Motor shows off air mobility, drone tech at Seoul defense fair
- ·Chief justice seat at top court left vacant amid Assembly chaos
- ·Seoul shares open lower on Fed, growth woes
- ·Manpower Korea’s unique approach to reference checks
- ·北, 日의 장거리미사일 조기 배치 추진에 “전쟁국가 일본 실체”
- ·Young swimmer enjoys self
- ·New government initiative offers W3b reward to combat digital piracy
- ·N. Korean envoy vows stronger 'self
- ·Hospital visits during Chuseok cost up to 50% more
- ·120,000 more public homes to be supplied by this year
- ·Biden says Hamas must be eliminated, US officials warn war could escalate
- ·보란듯 제재 무시하며 국제법 준수?…김정은 활용하는 푸틴의 속내는
- ·Young swimmer enjoys self
- ·北주민 굶어 죽어도…김여정 디오르, 최선희는 구찌 '명품 사랑'
- ·Cast of ‘Norma’ says opera difficult to sing but easy to enjoy
- ·Intangible cultural heritage exhibitions, performances head overseas